メインコンテンツにスキップ
検索
オンデマンド・ウェビナー

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

This webinar discusses the draft ICH M15 guidance. For the latest perspectives aligned with the final approved guidance, explore our updated webinar and readiness resources.

講演者

Hannah Jones
Hannah Jones

SVP, PBPK Consultancy Services, Certara

Rik de Greef
Dr. Rik de Greef

SVP, Quantitative Science Services, Certara

Dr. Krithika Shetty

Sr. Director, Clinical Pharmacology, Certara

Dr. Eva Gil Berglund

Sr. Director, Regulatory Strategy, Certara

ICH M15 Scorecard App
How ready is your MIDD strategy for ICH M15?

Get instant insights with our free interactive MIDD scorecard

Start your ICH M15 readiness assessment

関連コンテンツ

ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development
ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug DevelopmentBlog

ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development
FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug DevelopmentBlog

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)
Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)Guide

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Powered by Translations.com GlobalLink Web Software